Literature DB >> 26811667

Antibody markers in the diagnosis of inflammatory bowel disease.

Keiichi Mitsuyama1, Mikio Niwa1, Hidetoshi Takedatsu1, Hiroshi Yamasaki1, Kotaro Kuwaki1, Shinichiro Yoshioka1, Ryosuke Yamauchi1, Shuhei Fukunaga1, Takuji Torimura1.   

Abstract

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic intestinal inflammation of unknown etiology. The diagnosis of IBD is based on endoscopic, radiologic and histopathologic criteria. Recently, the search for a noninvasive marker that could augment or replace part of this diagnostic process has become a focus of IBD research. In this review, antibody markers, including microbial antibodies, autoantibodies and peptide antibodies, will be described, focusing on their common features. At present, no single marker with qualities that are satisfactory for the diagnosis and treatment of IBD has been identified, although panels of some antibodies are being evaluated with keen interest. The discovery of novel IBD-specific and sensitive markers is anticipated. Such markers could minimize the use of endoscopic and radiologic examinations and could enable clinicians to implement individualized treatment plans designed to improve the long-term prognosis of patients with IBD.

Entities:  

Keywords:  Biomarker; Crohn’s disease; Serological antibody; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 26811667      PMCID: PMC4716040          DOI: 10.3748/wjg.v22.i3.1304

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  Mycobacterium avium subsp. paratuberculosis in Crohn's disease is serologically positive.

Authors:  S Naser; I Shafran; F El-Zaatari
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.

Authors:  Cynthia H Seow; Joanne M Stempak; Wei Xu; Hui Lan; Anne M Griffiths; Gordon R Greenberg; A Hillary Steinhart; Nir Dotan; Mark S Silverberg
Journal:  Am J Gastroenterol       Date:  2009-04-21       Impact factor: 10.864

3.  Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.

Authors:  F M Ruemmele; S R Targan; G Levy; M Dubinsky; J Braun; E G Seidman
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

4.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  J F Quinton; B Sendid; D Reumaux; P Duthilleul; A Cortot; B Grandbastien; G Charrier; S R Targan; J F Colombel; D Poulain
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

5.  Isolation and characterization of a novel short peptide associated with Crohn's disease.

Authors:  K Mitsuyama; M Niwa; J Masuda; K Kuwaki; H Yamasaki; H Takedatsu; T Kobayashi; M Sata
Journal:  Clin Exp Immunol       Date:  2011-07-28       Impact factor: 4.330

6.  Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study.

Authors:  W J Sandborn; C J Landers; W J Tremaine; S R Targan
Journal:  Mayo Clin Proc       Date:  1996-05       Impact factor: 7.616

7.  Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils.

Authors:  P Gionchetti; M Vecchi; F Rizzello; M Ferretti; C Calabresi; A Venturi; M B Bianchi; C Brignola; R A Sinico; R De Franchis; M Miglioli; M Campieri
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

8.  Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.

Authors:  Anna Zholudev; David Zurakowski; Wes Young; Alan Leichtner; Athos Bousvaros
Journal:  Am J Gastroenterol       Date:  2004-11       Impact factor: 10.864

9.  Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.

Authors:  Peter Laszlo Lakatos; Istvan Altorjay; Tamas Szamosi; Karoly Palatka; Zsuzsanna Vitalis; Judit Tumpek; Sandor Sipka; Miklos Udvardy; Tamas Dinya; Laszlo Lakatos; Agota Kovacs; Tamas Molnar; Zsolt Tulassay; Pal Miheller; Zsolt Barta; Winfried Stocker; Janos Papp; Gabor Veres; Maria Papp
Journal:  Inflamm Bowel Dis       Date:  2009-03       Impact factor: 5.325

10.  Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease.

Authors:  R J Chiodini; H J Van Kruiningen; R S Merkal; W R Thayer; J A Coutu
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

View more
  37 in total

1.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

2.  Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies.

Authors:  Huijuan Wang; Shuhong Zhou; Jiahong Zhang; Shangwen Lei; Jing Zhou
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

Review 3.  Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases.

Authors:  Louis J Cohen; Judy H Cho; Dirk Gevers; Hiutung Chu
Journal:  Gastroenterology       Date:  2019-03-14       Impact factor: 22.682

Review 4.  Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis.

Authors:  Eric Gracey; Lars Vereecke; Dermot McGovern; Mareike Fröhling; Georg Schett; Silvio Danese; Martine De Vos; Filip Van den Bosch; Dirk Elewaut
Journal:  Nat Rev Rheumatol       Date:  2020-07-13       Impact factor: 20.543

5.  PAI-1 augments mucosal damage in colitis.

Authors:  Gerard E Kaiko; Feidi Chen; Chin-Wen Lai; I-Ling Chiang; Jacqueline Perrigoue; Aleksandar Stojmirović; Katherine Li; Brian D Muegge; Umang Jain; Kelli L VanDussen; Bridie J Goggins; Simon Keely; Jessica Weaver; Paul S Foster; Daniel A Lawrence; Ta-Chiang Liu; Thaddeus S Stappenbeck
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

6.  Antibodies to Crohn's disease peptide 353 as a diagnostic marker for pediatric Crohn's disease: a prospective multicenter study in Japan.

Authors:  Tatsuki Mizuochi; Katsuhiro Arai; Takahiro Kudo; Ryusuke Nambu; Hitoshi Tajiri; Tomoki Aomatsu; Naoki Abe; Toshihiko Kakiuchi; Kunio Hashimoto; Tsuyoshi Sogo; Michiko Takahashi; Yuri Etani; Yugo Takaki; Ken-Ichiro Konishi; Jun Ishihara; Hitoshi Obara; Tatsuyuki Kakuma; Shunsuke Kurei; Yushiro Yamashita; Keiichi Mitsuyama
Journal:  J Gastroenterol       Date:  2020-01-24       Impact factor: 7.527

Review 7.  Treatments of inflammatory bowel disease toward personalized medicine.

Authors:  Ki-Uk Kim; Jisu Kim; Wan-Hoon Kim; Hyeyoung Min; Chang Hwan Choi
Journal:  Arch Pharm Res       Date:  2021-03-24       Impact factor: 4.946

Review 8.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

9.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

10.  Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children.

Authors:  Elizabeth A Spencer; Sonia M Davis; David R Mack; Brendan M Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; David J Keljo; James F Markowitz; Susan S Baker; Joel R Rosh; Robert N Baldassano; Maria Oliva-Hemker; Marian D Pfefferkorn; Anthony R Otley; Melvin B Heyman; Joshua D Noe; Ashish S Patel; Paul A Rufo; M Alison Marquis; Thomas D Walters; Margaret H Collins; Subra Kugathasan; Lee A Denson; Jeffrey S Hyams; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2018-05-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.